90 likes | 173 Views
Treatment Prevalence Project Background information. Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013. Aim of the project. To have the total number of treatment clients in a country
E N D
Treatment Prevalence ProjectBackground information Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013
Aim of the project • To have the total number of treatment clients in a country • To collect data on the total number of drug addicts reached by treatment • To get the number of drug users in treatment for long period or more than one year • To have a picture of the profile of the treated population, including its characteristics
History of the project (1) • May 2005: proposal of the Dutch SC member • September 2005: discussion during the TDI expert meeting, NL presentation and setting up a working group • November 2005: proposal for a pilot project presented to NFPs • January 2006: working group meeting 9 volunteer countries and launch of pilot project • Summer 2006: 1st pilot data collection • Sep.-Nov. 2006 presentations first results during the TDI and RTX meeting
History of the project (2) • Summer 2007: 2nd pilot data collection • Summer 2007: feasibility assessment with NFPs • Sep.-Nov.2007: presentations results of 2nd pilot data collection and of the feasibility assessment (TDI and RTX meeting) • 2008: 3rd pilot data collection • 2008 until 2012: TDI revision: TDI prevalence as separated project • 2013: TDI prevalence included in the 2013 Work programme
Results from feasibility assessment (2007) 28 countries replied: 25 MS + TK + HR + NO2 countries not replying: RO, SI Source: Results from a survey to the NFPs on feasibility assessment
Reasons for collecting prevalence data(23 countries) • More complete information on the whole drug problem • Overview of drug treatment population: most part of treatment clients is not included in the current TDI data collection • More “realistic” picture on the number of drug clients • Useful data for treatment planning: it gives information on treatment capacities and treatment needs • Increase research and analysis potentialities with TDI data
Reasons for not collecting prevalence data(5 countries – DK, SP, GR, SW, NO) • Data collection: low feasibility (3 countries) or not feasible (2 countries) • Burden increase in the NFPs and treatment networks • Decrease in data quality • 50% increase in financial (between 20.000 and 300.000 euros) and human resources (between 3 and 5 staff members) in the implementation phase • Less for maintaining the information system • Not much added value to the information currently collected
Resources to be invested • No additional costs for 7 countries • Differences in the remaining countries • Human resources: between 1 and 8 staff • Financial resources: between 20 000 and 100 000 Euros (often including staff cost)
Additional feedback from NFPs and TDI experts • Agreement on implementing data collection on treatment prevalence • Clear definition/methodology needed • Only basic data should be collected